Cardiogen

Other Research Peptides

aka AEDR · Ala-Glu-Asp-Arg · H-Ala-Glu-Asp-Arg-OH

Compare

Formula

MW (Da)

Half-life

~few minutes

Saves

Overview

Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg, AEDR) typically described in patents as a myocardium-restoring peptide. The retrieved literature is almost entirely preclinical — rodent tissue and cultured cells — with no defined receptor and no modern clinical development.

Mechanism

Available studies do not identify a validated receptor or canonical signaling axis for cardiogen. The most-cited mechanistic data come from cultured mouse embryonic fibroblasts: H-Ala-Glu-Asp-Arg-OH increased expression of cytoskeletal proteins (actin, tubulin, vimentin) and nuclear-matrix proteins (lamin A, lamin C), which the authors interpreted as a pro-proliferative, anti-apoptotic phenotype. Rat myocardium explants treated with cardiogen also showed lower p53 expression, again implying anti-apoptotic effects rather than receptor pharmacology. Human pharmacokinetics were not provided in the retrieved literature; the evidence base is patent-centered.

0

Vendors

—

no vendors yet

Lowest price

—

Reported benefits

Cytoskeletal and nuclear-matrix protein upregulation (in vitro)

In cultured mouse embryonic fibroblasts, H-Ala-Glu-Asp-Arg-OH increased expression of actin, tubulin, vimentin, lamin A, and lamin C — interpreted by the authors as a mechanism for increased proliferation and reduced apoptosis.

[cardiogen-springer-2012]

preclinical

Reported pro-proliferative effects in rat myocardium tissue cultures

Cardiogen reportedly stimulated proliferation in rat myocardium tissue cultures from both young and old animals; effects in rat M-1 sarcoma also reported, weakening claims of strict cardiac selectivity.

[cardiogen-myocardium-pubmed]

preclinical

Reported side effects

No formal human adverse-event dataset
anecdotal
The patents and preclinical abstracts retrieved here do not provide a formal human adverse-event dataset or a modern toxicology package. Severity and frequency are unspecified in primary literature.

Dosing notes

Reported experimental concentrations exist in cell and tissue work, but accessible abstracts and patent snippets do not provide a reliable human dosing regimen. Human dose, route, schedule, and safety margin are unspecified.

Research use only. Information on this page is editorial reference, not medical or dosing advice. Always consult qualified medical guidance before use.

Storage

Peer-reviewed stability data were not identified. General research-peptide handling guidance recommends dry, light-protected refrigerated or frozen storage for lyophilized material, ideally below -20 °C (or -80 °C for long-term), with minimal freeze-thaw cycles after reconstitution. Treat this as supplier practice rather than validated pharmaceutical stability.

Vendors carrying Cardiogen

No approved vendors are listing this peptide yet. Check back later or browse the full vendor directory.

Discussion

Ask, answer, and vote on questions about Cardiogen.

No questions yet. Be the first to ask.

References

[cardiogen-patent-ep1758923]
EP1758923B1 — Peptide substance restoring myocardium function
Khavinson VK et al. (inventors) · European Patent Office
Source
[cardiogen-springer-2012]
Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins
Khavinson VK et al. · 2012 · Bulletin of Experimental Biology and Medicine
Source
[cardiogen-myocardium-pubmed]
The effect of the amino acids and cardiogen on proliferation in rat myocardium
Authors per PubMed entry · PubMed
Source
[sb-peptide-handling]
Peptide handling and storage guidelines
SB-Peptide · Vendor handling guide
Source